Hepatic effects of duloxetine-I: non-clinical and clinical trial data

• Published in: Current drug safety Vol. 3; no. 2; p. 132
• Main Authors: Wernicke, Joachim, Pangallo, Beth, Wang, Fujun, Murray, Isabelle, Henck, Judith W, Knadler, Mary Pat, D'Souza, Deborah N, Uetrecht, Jack P
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.05.2008
• Subjects: Adrenergic Uptake Inhibitors - adverse effects; Adrenergic Uptake Inhibitors - toxicity; Alanine Transaminase - blood; Alkaline Phosphatase - blood; Animals; Aspartate Aminotransferases - blood; Bilirubin - blood; Biomarkers - blood; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Consumer Product Safety; Drug Evaluation, Preclinical; Duloxetine Hydrochloride; Humans; Liver - drug effects; Liver - enzymology; Liver Diseases - enzymology; Risk Assessment; Risk Factors; Serotonin Uptake Inhibitors - adverse effects; Serotonin Uptake Inhibitors - toxicity; Species Specificity; Thiophenes - adverse effects; Thiophenes - toxicity

Review nonclinical and clinical trial data for hepatic effects of duloxetine. Review studies of toxicology, metabolism, mitochondrial effects, and clinical trials. Nonclinical studies revealed no treatment-related transaminase elevations and no effects of duloxetine on mitochondrial beta-oxidation i...